Posted by Michael Wonder on 08 Jul 2019
Withdrawals from the drug benefits - August 2019
8 July 2019 - Etalpha 80 mg & 100 capsules, Leflunomide medac 15 mg & 30 tablets and Maviret 100 mg - 40 mg tablets are among the medicines that leave the drug benefits at the company's request on August 1.
Maviret 100 mg - 40 mg tablets exits from the drug benefits at the company's request. As of 1 August 2019, the drug is no longer included in the benefits. Following the withdrawal of Maviret, other drugs remain in the benefits subsidised to patients with hepatitis C regardless of the fibrosis stage.
